Vivus VVUS

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Arena And VIVUS : A Case Study In Small-Cap Pharma

      Headlines

      Mon, 18 Aug 2014

      Pharmaceuticals (NASDAQ: ARNA ) and VIVUS Inc (NASDAQ: VVUS ) need no introduction. 2012 was ..... for Belviq on June 27, 2012. VIVUS 's Qsymia, a combination of phentermine ..... road to approval Both Arena and VIVUS saw their stocks bid up several

    2. 2nd Half Of 2014 Biotechnology Catalysts - Part 4

      Headlines

      Sun, 17 Aug 2014

      By Alexander Maxwell : Having previously updated the investment community in part 3 of my Biotechnology Catalysts series, the purpose of this article is to help give investors an idea of the upcoming biotechnology catalysts through the end of September. It can be hard for investors to be able to ...

    3. Belviq Sales Flatten Out But Edge Above Qsymia

      Headlines

      Fri, 15 Aug 2014

      week is that for the first time (using IMS Health numbers) Belviq sales were above the levels reported for Vivus 's (NASDAQ: VVUS ) Qsymia. Belviq edged out Qsymia by a handful of scripts via the fact that week over week numbers for Qsymia

    4. FDA Data: Good News For One Anti-Obesity Company, Not So Good For Another

      Headlines

      Fri, 15 Aug 2014

      number of scripts sold. I analyzed the data for Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) and Qsymia from Vivus (NASDAQ: VVUS ). There are a couple of items that investors should consider when looking at what I am presenting here: An adverse

    5. Arena's Belviq Bucks Seasonality With 3.6% Week Over Week Gain

      Headlines

      Fri, 8 Aug 2014

      By Spencer Osborne : Sales of the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) continue to buck the seasonality of the weight loss sector with a 3.6% week over week gain. While 3.6% may not seem impressive, investors must consider that the second half of the year typically ...

    6. Vivus Beats The Street - Still Has A Loss

      Headlines

      Fri, 8 Aug 2014

      By Spencer Osborne : Vivus (NASDAQ: VVUS ) announced its quarterly earnings today and beat the street by $0 ..... second quarter of 2013. For STENDRA® and SPEDRA™, Vivus recognized $4.2 million in license and milestone revenue

    7. VIVUS' ( VVUS ) CEO Seth Fischer on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 7 Aug 2014

      VIVUS Inc (NASDAQ: VVUS ) Q2 2014 Earnings Conference Call August ..... ladies and gentlemen, and welcome to the VIVUS Second Quarter 2014 Financial Results Teleconference ..... remind you that during this conference call, VIVUS will Complete Story »

    8. More on Vivus Q2 results

      Headlines

      Thu, 7 Aug 2014

      Vivus ( VVUS -0.4% ) Q2 results : Revenues: $21.9M (+295.4%); Qsymia Sales: $11.0M (+100.0%); Operating Expenses

    9. Vivus ( VVUS ) Q2 2014 Results - Earnings Call Webcast

      Headlines

      Thu, 7 Aug 2014

      The following audio is from a conference call that will begin on August 07, 2014 at 16:30 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »

    10. Orexigen Hits Expectations But That Is Not The Big News

      Headlines

      Thu, 7 Aug 2014

      By Spencer Osborne : Orexigen (NASDAQ: OREX ) announced its Q2 financial results this morning and the loss of $0.21 cents came in line with expectations. The equity moved up early in the session because of positive outlooks for the anti-obesity drug NB32, also known as Contrave. Orexigen is ...

    « Prev12345Next »
    Content Partners